Visgo is developing therapies to locally treat joint diseases. We have developed a breakthrough platform technology using chitosan microparticles for intra-articular (IA) delivery of therapies over time within the synovial membrane; the particles can be used to delivery small molecules, large molecules, proteins and cell. Our lead program, VG201, delivers a very low dose of the potent NSAID diclofenac directly to the site of osteoarthritis (OA) inflammation in the synovium, resulting in reduced inflammation and pain. It is being developed under the FDA’s abbreviated 505(b)(2) drug approval pathway, initially to treat knee OA pain, with the potential to be on the market in 5 years. Given the large medical need for safe and effective non-surgical therapies to treat OA, we expect VG201 to have a rapid uptake by orthopedic surgeons, rheumatologists and pain specialists. Visgo is privately held and based in Boston, MA.